FDA approves oral treatment for adults with ADHD

Supernus Pharmaceuticals announced FDA approval of viloxazine extended-release capsules to treat ADHD in patients aged 18 years and older.
The FDA has now given its consent to viloxazine (Qelbree, Supernus), a once-per-day oral nonstimulant for the treatment of ADHD, starting with children aged 6 years, as well as adolescents and adults, a company press release stated.
“As a leader in the field of (treating central nervous system disorders), we are fully committed to better understanding how to treat complex diseases such as ADHD,” Jack Khattar, president and CEO of Supernus said in

Supernus Pharmaceuticals announced FDA approval of viloxazine extended-release capsules to treat ADHD in patients aged 18 years and older.
The FDA has now given its consent to viloxazine (Qelbree, Supernus), a once-per-day oral nonstimulant for the treatment of ADHD, starting with children aged 6 years, as well as adolescents and adults, a company press release stated.
“As a leader in the field of (treating central nervous system disorders), we are fully committed to better understanding how to treat complex diseases such as ADHD,” Jack Khattar, president and CEO of Supernus said in